1. WHO. Emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin monotherapy from the market. Geneva, Switzerland: World Health Organization. 2014.
http://www.who.int/malaria/publications/atoz/oral-artemisinin-based-monotherapies-1may2014.pdf
. Accessed 31 May 2017.
2. WHO. Status report on artemisinin resistance. Geneva, Switzerland: World Health Organization. 2014.
http://www.who.int/malaria/areas/drug_resistance/updates/en/
. Accessed 31 May 2017.
3. ACTwatch Group. Malaria market trends in sub-Saharan Africa: 2009–2014. PSI, Washington, DC: PSI. 2016.
4. ACTwatch Group, Phok S, Phanalasy S, Thein ST, Likhitsup A. Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand. Malar J. 2017;16:180.
5. Khin HS, Aung T, Thi A, White C, ACTwatch Group. Oral artemisinin monotherapy removal from the private sector in Eastern Myanmar between 2012 and 2014. Malar J. 2016;15:286.